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Abstract LDL-apheresis is a method to correct dyslipi-
demia rapidly. It is expected to alleviate the tissue toxicity
of persistent dyslipidemia in not only primary, but also in
secondary dyslipidemia associated with refractory
nephrotic syndrome, and to have a protective effect against
glomerular and tubular injury as expected in atherosclero-
sis. In addition, the effectiveness of LDL-apheresis to
promote the remission of nephrotic syndrome has been
recognized. In Japan, LDL-A to control hyperlipidemia in
patients with refractory nephrotic syndrome associated
with focal segmental glomerulosclerosis is covered by
national health insurance. Here, the hypothetical mecha-
nism behind its effect and the evidence for its effectiveness
over a long period are reviewed.
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Introduction
Secondary dyslipidemia associated with refractory
nephrotic syndrome (NS), typically that due to focal seg-
mental glomerulosclerosis (FSGS), persists over a long
period, causes the progression of cardiovascular disease
with a course similar to arteriosclerotic lesions due to
primary dyslipidemia, and exacerbates damage to affected
glomeruli and renal tubules. LDL-apheresis (LDL-A) is a
method to correct dyslipidemia rapidly. It is expected to
alleviate the tissue toxicity of persistent dyslipidemia in
this disease and to have a protective effect on the kidney. In
addition, the effectiveness of apheresis therapy including
plasmapheresis to promote the remission of NS has been
recognized [1], but that of LDL-A has been suggested not
necessarily to be due to the correction of abnormal lipid
levels. At present, in Japan, LDL-A to control hyperlipid-
emia in patients with refractory NS associated with focal
glomerulosclerosis FSGS is covered by national health
insurance up to 12 times over 3 months, but clarification of
the mechanism of the effect of this treatment and evidence
for its effectiveness to maintain remission over a long
period have been insufficient. Prospective cohort studies
are being carried out, leading to the accumulation of evi-
dence on its efficacy and clarification of cases in which the
therapy is expected to be effective.
Definition of refractory NS and characteristics
of causative disorders
The international and Japanese diagnostic criteria for NS
are nearly the same. Urinary excretion of protein [3.5 g/
day, together with serum albumin at 3 g/day or less or
serum total protein level of 6 g/day or less (these are
essential diagnostic conditions), is expected to be main-
tained in association with edema and hypercholesterolemia
(not essential items). Concerning the criteria of remission,
in Japan, categories of type I and II incomplete remission
(ICR) have been established, in addition to the interna-
tional criteria of urinary excretion of protein at 1 g/day or
less and 1–3.5 g/day, respectively. In Japan, refractory NS
is defined as an inability to achieve type I ICR or complete
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remission (CR) despite the continuation of various treat-
ments over 6 months or longer. The outcome was inter-
nationally reported to have been significantly poorer in
those who were not included in these categories than in
those who were, based on a survey of a large number of
patients in Japan, and these categories are in wide clinical
use and have been retained in diagnostic and therapeutic
guidelines. Of the 3 major disorders considered to be
causes of primary NS, FSGS and membranous nephropa-
thy (MN) may develop into refractory NS. The patholog-
ical clarification of FSGS has advanced recently, and the
nephrotoxicity of dyslipidemia associated with this disease
has been reported. LDL-A was initiated against this dis-
ease in particular.
Mechanism of occurrence of hyperlipidemia in NS
and tissue toxicity of lipids
Marked proteinuria due to NS causes severe hypoalbumi-
nemia, promotes lipoprotein synthesis, and induces exces-
sive albumin synthesis, resulting in hypercholesterolemia.
Hypercholesterolemia is also promoted by metabolic dis-
orders due to the loss of lipoprotein lipases that degrade
LDL and VLDL cholesterols. LDL, particularly oxidized
LDL, is incorporated by mesangial cells with scavenger
receptors, forming foam cells. The foam cells and induced
macrophages express various inflammatory cytokines and
chemokines and cause tissue damage (Fig. 1) [2]. In
addition, a large amount of protein leaks into the urine, but
detached tubular cells that have absorbed fat are often
observed. These reabsorbed excess lipids are considered to
damage tissues by intensifying oxidative stress in the renal
tubules [3]. Typical findings such as the frequent
appearance of interstitial foam cells are observed in FSGS,
in which dyslipidemia persists.
Anti-nephropathic effect of the correction
of hyperlipidemia associated with nephrotic syndrome
The secondary dyslipidemia mentioned above can be cor-
rected by statins over a long period, but by LDL-A if an
acute effect is expected. In LDL-A using a dextran sulfate
column (Liposorber, Kaneka), which is prepared by coating
porous Sepharose beads with dextran sulfate, LDL-cho-
lesterol is adsorbed due to an electrostatic interaction
between negatively charged dextran sulfate and positively
charged apoprotein B on the surface of lipoprotein. VLDL
and LDL are selectively adsorbed, but no HDL-cholesterol
with ApoA or other plasma components including albumin
is adsorbed. Liposorber can purify 3–4,000 ml of plasma in
2–3 h. When Sakai et al. first carried out this treatment for
FSGS in 1988 in Japan, not only the correction of hyper-
lipidemia, but also rapid resolution of NS was observed, so
coverage by national health insurance was extended to its
application to FSGS with hyperlipidemia (LDL-cholesterol
[250 mg/dl) in 1989.
Evaluation of the mechanism of the effects of LDL-A
(Table 1)
Effects of adsorption of LDL, particularly oxidized
LDL
The infiltration of lesions by macrophages induces cyto-
kines and chemokines such as TNFa and IL-8, which are
Fig. 1 Lipid nephrotoxicity
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elevated in the serum of nephrotic patients, and causes
inflammation and the activation of mesangial cells. LDL
scavenger receptors present in these macrophages are
likely to be hyperstimulated by an increase in LDL-cho-
lesterol, particularly oxidized LDL, in the circulation.
Evaluation of the effect of LDL-A on LPS-stimulated IL-8
production by peripheral monocytes by its comparison
between before and after treatment revealed significant
suppression of the responsiveness compared with that in
healthy subjects before treatment, but this was significantly
recovered after treatment [6]. This is considered to have
been due to the recovery of macrophage function caused by
the rapid elimination of LDL.
Inflammatory cytokines such as TNFa and IL-8 are
significantly expressed in the blood of nephrotic patients,
irrespective of the causative disease [4]. We observed that
elevated IL-8 level was significantly reduced in the blood
after comparison with that before several sessions of LDL-
A (data not shown). This decrease in IL-8 derived from
macrophages is considered to indicate the resolution of
macrophage hyperstimulation.
Adsorption of humoral factors responsible for NS
Savin et al. established an in vitro method to determine the
albumin permeability of the glomeruli, and showed that the
plasma of NS patients significantly increases the perme-
ability. They also analyzed the patients’ plasma for
humoral factors responsible for disease, and identified them
as mildly acidic (pH 6.0) materials with a size of 30–50 kD
[5]. However, the relationship between these factors and
the occurrence of FSGS is unknown. In consideration of
the involvement of these humoral factors, it is interesting
that plasmapheresis and sometimes LDL-A, carried out in
patients who showed recurrence after kidney transplanta-
tion, have been successful to a degree [6]. Another obser-
vation revealed that impaired IFN-c production under IL12
stimulation of peripheral blood in persistent NS was
restored by LDL-A, possibly through the removal of
interfering serum factors [7].
Recovery of cell sensitivity to drugs
In patients with CyA-sensitive FSGS, we have sometimes
experienced that LDL-A recovered CyA effects at the
same serum CyA concentration as had previously been
refractory, especially in a relapse state. In terms of the
mechanism behind this effect, CyA receptors taken into
cells through binding with LDL are considered to have
been saturated due to a high LDL level, preventing its
absorption into the cells, but the rapid elimination of LDL
is considered to have induced the recovery of the receptor
function.
Reports of evidence of therapeutic effects and trials
LDL-A was performed in 17 patients with FSGS not
responding to steroid therapy that had been continued for
1 month or longer; the effect of the treatment and the
remission rate were compared with those in 10 patients
treated with steroids alone. Of the 17 patients who under-
went LDL-A, CR was observed in 8 and type I ICR in 4;
these results were significantly better than CR in 2 and type
I ICR in 1 in the steroid alone group. More importantly, the
time required to reduce proteinuria to 3.5 g/day, which is a
criterion of NS, was markedly shorter in the LDL-A group.
As a result, the steroid dose could be reduced earlier by the
combination of steroid therapy and LDL-A. The remission
rate was further increased in a follow-up study 2 years
later, suggesting that the prognosis of even FSGS with
refractory NS is favorable if remission can be achieved [8].
Table 1 Hypothetical mechanism of action of LDL-A on refractory
NS
1. Direct effect of lipid (LDL, VLDL, oxLDL) adsorption
(1) Reduction of macrophage stimulation by ox-LDL
(2) Amelioration of macrophage dysfunction
(3) Reduction of inflammatory cytokine
2. Vasodilatory and anticoagulant effect by absorption of various
pathogenic factors by dextran sulfate
(1) Reduction of fibrinogen and coagulatory factors
(2) Increase of VEGF/NO/bradykinin production, and decrease in
thromboxane A2
(3) Absorption of vascular permeability factor
3. Enhancement of response immunosuppressant by amelioration
of intracellular drug transport
(1) Amelioration of corticosteroid response
(2) Enhancement of transmembrane cyclosporine A transport via
lipoprotein receptor
(3) Restore via inhibitory effects upon MDR-1 gene expression
Fig. 2 Retrospective survey of outcome of FGS patients with
refractory NS treated by LDL-apheresis. Two-year outcome of 29
FSGS patients (a) and 5-year outcome of 15 patients (b) are shown
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A survey concerning the long-term outcome was con-
ducted primarily by the Japanese Society of Kidney and
Lipids with the cooperation of 36 facilities, involving 94
patients with refractory nephrotic syndrome including 41
patients with FSGS and 28 patients with refractory minimal
change nephrotic syndrome (MCNS) who underwent LDL-
A in 1999 and thereafter [9]. The profiles of the FSGS and
MCNS patients were as follows: male/female ratio: 24/16
and 14/14; mean age: 43 ± 19.6 and 35.7 ± 18.7 years;
initial/recurrence ratio: 20/15 and 12/14; number of LDL-A
trials: 8.25 ± 2.87 and 8.00 ± 5.57; and ratio between
those who underwent kidney transplantation and those who
did not: 7/24 and 0/25, respectively. In terms of the fre-
quency of use of various drugs, steroids were used in 88
and 93 %, steroid pulse therapy was performed in 29 and
57 % (the prescription was the same as that before the
initiation of LDL-A, except in 1 patient with MCNS),
immunosuppressants were used in 41 and 46 %, CyA was
employed in 29 and 36 %, and statins were used in 44 and
36 %, respectively. The percentages of patients who were
included in the category of type I ICR after 2 years were 62
and 95 %, and those after 5 years were 87 and 80 %,
respectively. Those of FSGS are shown in Figure 2. The
response became more favorable as the time from the onset
of NS to the introduction of LDL-A decreased.
Since the above studies were retrospective, a prospec-
tive cohort study (Prospective Observational Survey on the
Long-Term Effects of LDL-A on Drug-Resistant Nephrotic
Syndrome (POLARIS)) was initiated by the Japanese
Society of Kidney and Lipids. In the preliminary analysis,
almost the same remission rate was obtained, even in
prospective study (under submission).
As shown in Table 2, on the basis of reported results of
retrospective studies, LDL-A has been effective for
inducing remission in nearly 50 % of patients with various
diseases including FSGS that was refractory to NS, with a
high level of safety. As noted in recently renewed guide-
lines for NS in Japan (2013), LDL-A should be selected as
an option for the strategy to treat refractory NS.
Acknowledgments The author would like to thank Drs. Soichi
Sakai, Masatoshi Mune, Tsutomu Hirano, Motoshi Hattori, Kenjiro
Kimura, Tsuyoshi Watanabe, Hitoshi Yokoyama, Hiroshi Sato, Shu-
nya Uchida, Takashi Wada, Tetsuo Shoji, Tsukasa Takemura, Yukio
Yuzawa, Hiroaki Oda, Kiyoshi Mori, and Takao Saito for their
support as members of the Japanese Society of Kidney and Lipids.
The author also thanks Drs. Hitomi Miyata, Mari Maeda, and Hiro-
yuki Matsushima for their contributions to patient care and related
studies.
Conflict of interest There is no conflict of interest in the prepara-
tion and submission of this manuscript.










Muso et al. NDT
1994 9 2257-264
Sakai et al. Jin To
Touseki 1994 33
321–328
Hattori et al. Am
J Kidney Dis 42
1121–1130
Study design Study Group:
prospective


















MN ? FSGS (1)







2/w 9 3 1/w 9 7
Total 13
2/w 9 3 Total 6 2-13 7.3 (average) 2/w 9 3 Total 6 2/w 9 3






PSL 1.0 mg/kg none (4) PSL(1)
PSL ? CyA (2)






































glomerulus 5 in 6
cases







Clin Exp Nephrol (2014) 18:286–290 289
123
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Sulowicz W, Stompor T. LDL-apheresis and immunoadsorption:
novel methods in the treatment of renal diseases refractory to
conventional therapy. Nephrol Dial Transplant. 2003;18:v59–62.
2. Moorhead JF, Chan MK, El-Nahas M, et al. Lipid nephrotoxicity
in chronic progressive glomerular and tubulo-interstitial disease.
Lancet. 1982;2(8311):1309–11.
3. Ong AC, et al. Tubular lipidosis: epiphenomenon or pathogenetic
lesion in human renal disease? Kidney Int. 1994;45:753–62.
4. Sakurai M, Muso E, Matsushima H, Ono T, Sasayama S. Rapid
normalization of interleukin-8 production after low-density
lipoprotein apheresis in steroid-resistant nephrotic syndrome.
Kidney Int Suppl. 1999;71:S210–2.
5. Savin VJ, McCarthy ET, Sharma M. Permeability factors in focal
segmental glomerulosclerosis. Semin Nephrol. 2003;23(2):147–60.
6. Dantal J, Bigot E, Bogers W, et al. Effect of plasma protein
adsorption on protein excretion in kidney-transplant recipients
with recurrent nephrotic syndrome. N Engl J Med.
1994;330(1):7–14.
7. Miyata H, Uno K, Ono T, Yashiro M, Fukatsu A, Kita T, Kimura
T, Muso E. Low density lipoprotein apheresis ameliorates inter-
feron-c production in patients with nephrotic syndrome. Ther
Apher Dial. 2012;16(2):189–94.
8. Muso E, Mune M, Fujii Y, et al. Significantly rapid relief from
steroid resistant nephrotic syndrome by LDL-apheresis compared
with steroid monotherapy. Nephron. 2001;89(4):408–15.
9. Muso E, Mune M, Yorioka N, et al. Beneficial effect of low-
density lipoprotein apheresis (LDL-A) on refractory nephrotic
syndrome (NS) due to focal glomerulosclerois (FGS). Clin
Nephrol. 2007;67(6):341–4.
10. Yokoyama H, et al. Jpn J Apheresis. 2006;25(1):31–7 (in
Japanese).
290 Clin Exp Nephrol (2014) 18:286–290
123
